Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation
Launched by HANNOVER MEDICAL SCHOOL · Jan 7, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how specific treatments, including immunoglobulins, plasmapheresis (a procedure that cleans the blood), and rituximab (a medication that targets certain immune cells), can help manage donor-specific antibodies in patients who have received a lung transplant. These antibodies can sometimes cause problems by attacking the transplanted lung, so understanding how to monitor and treat them is important for improving patient outcomes.
If you or a loved one has had a lung transplant and has been found to have donor-specific antibodies, you may be eligible to participate in this study. There are no age or gender restrictions, and all lung transplant patients with these antibodies are welcome to join. As a participant, you can expect to be closely monitored during the study to see how effective these treatments are in managing your antibody levels. This research aims to provide valuable insights that could lead to better care for future lung transplant recipients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients after lung transplantation with detection of donor-specific antibodies
- Exclusion Criteria:
- • none
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, , Germany
Patients applied
Trial Officials
Fabio Ius, Dr.
Principal Investigator
Hannover Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials